Swiss National Bank Relmada Therapeutics, Inc. Transaction History

Swiss National Bank

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 09, 2022	BUY	$18.3 - $37.02 $120,780 - $244,332	6,600 Added 14.13%	53,300 $1.97 Million
Q2 2022 Aug 09, 2022	SELL	$16.5 - $30.34 $155,100 - $285,196	-9,400 Reduced 16.76%	46,700 $887,000
Q1 2022 May 09, 2022	BUY	$16.72 - $26.99 $68,552 - $110,659	4,100 Added 7.88%	56,100 $1.51 Million
Q4 2021 Feb 08, 2022	BUY	$16.93 - $26.82 $440,180 - $697,320	26,000 Added 100.0%	52,000 $1.17 Million
Q3 2021 Nov 08, 2021	BUY	$21.86 - $34.77 $19,674 - $31,293	900 Added 3.59%	26,000 $681,000
Q2 2021 Aug 06, 2021	SELL	$29.55 - $39.15 $135,930 - $180,090	-4,600 Reduced 15.49%	25,100 $803,000
Q1 2021 May 07, 2021	BUY	$31.52 - $39.28 $22,064 - $27,496	700 Added 2.41%	29,700 $1.05 Million
Q4 2020 Feb 05, 2021	BUY	$29.88 - $39.8 $41,832 - $55,719	1,400 Added 5.07%	29,000 $930,000
Q3 2020 Nov 09, 2020	BUY	$34.42 - $43.78 $34,420 - $43,780	1,000 Added 3.76%	27,600 $1.04 Million
Q2 2020 Aug 05, 2020	BUY	$31.59 - $49.98 $840,294 - $1.33 Million	26,600 New	26,600 $1.19 Million

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.